Dudley Robert Michael
SEC CIK 1854161 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RNAZ | Transcode Therapeutics, Inc. | CEO, Dir, 10% | 180.3K | $281.8K | — | 6 | 2022-05-27 | 2023-09-28 |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-02 | 2023-09-28 | RNAZ | Transcode Therapeutics, Inc. | Dudley Robert Michael | CEO, Dir | P - Purchase | $0.51 | +98.0K | 180.3K | +119% | +$50.0K | |
| M | 2023-06-22 | 2023-06-20+ | RNAZ | Transcode Therapeutics, Inc. | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.61 | +18.6K | 70.3K | +36% | +$48.6K |
| A | 2023-06-14 | 2023-06-09 | RNAZ | Transcode Therapeutics, Inc. | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.76 | +19.0K | 61.2K | +45% | +$52.4K |
| 2023-06-13 | 2023-06-09 | RNAZ | Transcode Therapeutics, Inc. | Dudley Robert Michael | CEO, Dir | P - Purchase | $2.76 | +19.0K | 912.1K | +2% | +$52.4K | |
| 2022-09-16 | 2022-09-14 | RNAZ | Transcode Therapeutics, Inc. | Dudley Robert Michael | CEO, Dir, 10% | P - Purchase | $1.15 | +20.0K | 893.1K | +2% | +$23.0K | |
| M | 2022-06-01 | 2022-05-27+ | RNAZ | Transcode Therapeutics, Inc. | Dudley Robert Michael | CEO, Dir, 10% | P - Purchase | $1.84 | +30.0K | 873.1K | +4% | +$55.3K |
Purchase Sale Sale after option exercise All abbreviations